One interpretation is that oncogenic G12 mutations may be superior to Q61 mutations in some manner, which is interesting insofar as G12 mutations are more common in KRAS than Q61 mutations in human cancers (Prior et al., 2020). This evidence concerns the gene KRAS and cancer.